PFS
DNTH icon

Prospera Financial Services’s Dianthus Therapeutics DNTH Stock Holding History

Prospera Financial Services’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-216
Closed -$23K – 884
2020
Q3 		$23K Buy
+216
New +$25.6K 0.01% 859

Other funds holding DNTH

TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Prospera Financial Services's DNTH Position: Q4 2020 in Review

Prospera Financial Services sold out of Dianthus Therapeutics (DNTH) in Q4 2020, closing a stake of 216 shares — an estimated $23K sold.

Prospera Financial Services first reported a position in DNTH in Q3 2020 and held it in 1 quarter. The position peaked at $23K in Q3 2020. 92 funds tracked by Wall St. Rank hold DNTH as of Q4 2020.

  • Prospera Financial Services reported no remaining Dianthus Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Prospera Financial Services sold 216 Dianthus Therapeutics shares in Q4 2020, an estimated $23K.
  • Prospera Financial Services first reported a position in Dianthus Therapeutics in Q3 2020 and held it in 1 quarter.
  • Prospera Financial Services's Dianthus Therapeutics position peaked at $23K in Q3 2020.
  • 92 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q4 2020.

Based on Prospera Financial Services's 13F filing for Q4 2020, filed 12 Feb 2021.